Lisata Therapeutics Valuation
| LSTA Stock | USD 2.65 0.01 0.38% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Lisata Therapeutics secures a last-minute Real Value of $2.17 per share. The latest price of the firm is $2.65. Our model forecasts the value of Lisata Therapeutics from analyzing the firm fundamentals such as Operating Margin of (21.66) %, shares outstanding of 8.6 M, and Return On Equity of -0.57 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Lisata Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Lisata Therapeutics is based on 3 months time horizon. Increasing Lisata Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lisata Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lisata Stock. However, Lisata Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.65 | Real 2.17 | Hype 2.65 | Naive 2.36 |
The real value of Lisata Stock, also known as its intrinsic value, is the underlying worth of Lisata Therapeutics Company, which is reflected in its stock price. It is based on Lisata Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lisata Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lisata Therapeutics helps investors to forecast how Lisata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lisata Therapeutics more accurately as focusing exclusively on Lisata Therapeutics' fundamentals will not take into account other important factors: Lisata Therapeutics Total Value Analysis
Lisata Therapeutics is now anticipated to have valuation of (3.04 M) with market capitalization of 22.7 M, debt of 137 K, and cash on hands of 72.99 M. The negative valuation of Lisata Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Lisata Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.04 M) | 22.7 M | 137 K | 72.99 M |
Lisata Therapeutics Investor Information
About 20.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lisata Therapeutics recorded a loss per share of 2.3. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 15th of September 2022. Based on the key indicators related to Lisata Therapeutics' liquidity, profitability, solvency, and operating efficiency, Lisata Therapeutics is not in a good financial situation at the present time. It has a very high chance of going through financial crunch in August.Lisata Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lisata Therapeutics has an asset utilization ratio of 2.86 percent. This suggests that the Company is making $0.0286 for each dollar of assets. An increasing asset utilization means that Lisata Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Lisata Therapeutics Ownership Allocation
The market capitalization of Lisata Therapeutics is $22.7 Million. Lisata Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Lisata Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1000 K. Net Loss for the year was (19.98 M) with profit before overhead, payroll, taxes, and interest of 1000 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lisata Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lisata Therapeutics and how it compares across the competition.
About Lisata Therapeutics Valuation
The stock valuation mechanism determines Lisata Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Lisata Therapeutics. We calculate exposure to Lisata Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lisata Therapeutics's related companies.Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease andor promote the regeneration of damaged tissue. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Lisata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people.
Lisata Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 8.3 M |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |